Evidence map›Paper›PMID 36289662›Full record

ArticleBiomedicines2022

Next-Generation SINE Compound KPT-8602 Ameliorates Dystrophic Pathology in Zebrafish and Mouse Models of DMD.

Katherine G English, Andrea L Reid, Adrienne Samani, Gerald J F Coulis, S Armando Villalta, Christopher J Walker, Sharon Tamir, Matthew S Alexander

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Katherine G EnglishDepartment of Pediatrics, Division of Neurology at Children's of Alabama the University of Alabama at Birmingham, Birmingham, AL 35233, USA.ORCID 0000-0003-2757-5157
Andrea L ReidDepartment of Pediatrics, Division of Neurology at Children's of Alabama the University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Adrienne SamaniDepartment of Pediatrics, Division of Neurology at Children's of Alabama the University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Gerald J F CoulisDepartment of Physiology and Biophysics, University of California-Irvine, Irvine, CA 92697, USA.
S Armando VillaltaDepartment of Physiology and Biophysics, University of California-Irvine, Irvine, CA 92697, USA.ORCID 0000-0002-5212-2259
Christopher J WalkerKaryopharm Therapeutics, Newton, MA 02459, USA.
Sharon TamirKaryopharm Therapeutics, Newton, MA 02459, USA.ORCID 0000-0003-0820-1184
Matthew S AlexanderDepartment of Pediatrics, Division of Neurology at Children's of Alabama the University of Alabama at Birmingham, Birmingham, AL 35233, USA.ORCID 0000-0001-7406-5171

Funding

UAB Pilot Center for Precision Animal Modeling (C-PAM) - Resource and Service SectionU54OD030167 · OD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Bradley K. Yoder · 2020 to 2026
$15.3M
Novel macrophage and regulatory T cell interactions that promote the pathogenesis of Duchenne muscular dystrophyR01NS120060 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI VILLALTA, SERGIO ARMANDO · 2020 to 2024
$2.5M
A MIR-486/DOCK3 SIGNALING AXIS MODULATES DYSTROPHIN-DEFICIENT PATHOLOGYR01HD095897 · NICHD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ALEXANDER, MATTHEW SCOTT · 2018 to 2022
$1.6M
UAB Training Program In NeuroscienceT32NS095775 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Erik D Roberson · 2017 to 2026
$1.6M
Tolerization of dystrophin and adeno-associated virus immunityR21NS114918 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI VILLALTA, SERGIO ARMANDO · 2020 to 2020
$431k
Micro RNAs as biomarkers and therapeutic targets in myotubular myopathyR21AR074006 · NIAMS · HOSPITAL FOR SICK CHLDRN (TORONTO) · PI ALEXANDER, MATTHEW SCOTT, DOWLING, JAMES J · 2018 to 2019
$337k
NIAMS NIH HHS R21 AR074006NIAMS NIH HHS R21AR074006NICHD NIH HHS R01 HD095897NIH HHS U54 OD030167NINDS NIH HHS 5T32NS095775NINDS NIH HHS R01 NS120060NINDS NIH HHS R01NS120060NINDS NIH HHS R21 NS114918NINDS NIH HHS R21NS114918NINDS NIH HHS T32 NS095775
6 · The paper itself

Abstract

Duchenne muscular dystrophy (DMD) is a progressive, X-linked childhood neuromuscular disorder that results from loss-of-function mutations in the DYSTROPHIN gene. DMD patients exhibit muscle necrosis, cardiomyopathy, respiratory failure, and loss of ambulation. One of the major driving forces of DMD disease pathology is chronic inflammation. The current DMD standard of care is corticosteroids; however, there are serious side effects with long-term use, thus identifying novel anti-inflammatory and anti-fibrotic treatments for DMD is of high priority. We investigated the next-generation SINE compound, KPT-8602 (eltanexor) as an oral therapeutic to alleviate dystrophic symptoms. We performed pre-clinical evaluation of the effects of KPT-8602 in DMD zebrafish (

Indexed as

DMDinflammationKPT−8602SINE compound

Identifiers

PMID36289662
PMCPMC9598711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.